SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Roche: Gazyva/Gazyvaro Becomes First FDA-Approved Treatment For Primary Membranous Nephropathy In Adults

Phase III MAJESTY Trial Shows 36.1% Complete Remission At Two Years Versus 5.7% With Tacrolimus

Related stories